<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795988</url>
  </required_header>
  <id_info>
    <org_study_id>IMU.ACS.001</org_study_id>
    <nct_id>NCT02795988</nct_id>
  </id_info>
  <brief_title>A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer</brief_title>
  <official_title>A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imugene Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imugene Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the&#xD;
      safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131. The RP2D&#xD;
      will be evaluated in the dose expansion Phase 2 study. The Phase 2 study is a randomized,&#xD;
      open label comparison of IMU-131 plus standard of care chemotherapy versus standard of care&#xD;
      chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMU-131 is a single peptide structure composed of 3 individual B-cell epitope peptide&#xD;
      sequences selected from HER2/neu structure. Polyclonal antibodies against IMU-131 peptides&#xD;
      bind three separate regions of the HER2 receptor and also to the dimerization loop of the&#xD;
      HER2 receptor, preventing dimerization, which in turn inhibits intracellular signaling. This&#xD;
      blockade of the HER2 signaling pathways is thought to be substantially greater than that with&#xD;
      trastuzumab alone. Safety and immunogenicity of the 3 peptides have been shown in Phase 1a&#xD;
      testing of an earlier formulation of IMU-131. The shelf stability of the Phase 1a vaccine was&#xD;
      not optimal and hence the formulation was adjusted for IMU-131. The three B-cell epitope&#xD;
      peptides (P4, P6 and P7) were combined in a specific order resulting in a single fusion&#xD;
      peptide of 49 amino acids in length (P467). This new formulation of IMU-131 has extended&#xD;
      stability and improved immunogenicity compared to the formulation used previously. The new&#xD;
      vaccine IMU-131 produces a stronger and more rapid polyclonal antibody response and is&#xD;
      efficient to manufacture compared with previous formulations. Based on these three known&#xD;
      epitopes (P4, P6 and P7), the investigators developed a single peptide antigen (P467), which&#xD;
      allows simplification of the manufacturing process.&#xD;
&#xD;
      It is hypothesized that administration of IMU-131 in addition to chemotherapy will prolong&#xD;
      survival and may delay tumor progression and/or reduce tumor burden in patients with HER2/neu&#xD;
      overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma (otherwise known as&#xD;
      Advanced Cancer of the Stomach (ASC)).&#xD;
&#xD;
      The Phase 1b study aims to determine the safety and tolerability of IMU-131 and identify the&#xD;
      Recommended Phase 2 Dose (RP2D) of IMU-131 in combination with chemotherapy in HER2/neu&#xD;
      overexpressing ACS to carry into the Phase 2 dose expansion study. The Phase 2 component will&#xD;
      be submitted as an amendment and will be initiated following completion of Phase 1b. Phase 2&#xD;
      will be designed to further characterize the safety and to explore clinical activity of&#xD;
      IMU-131 in combination with chemotherapy in HER2/neu overexpressing ACS.The Phase 2 study is&#xD;
      a randomized, open label comparison of IMU-131 plus standard of care chemotherapy versus&#xD;
      standard of care chemotherapy alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Partially blinded - blinded central review of progression.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of IMU-131 (Phase 1b)</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>The safety and tolerability of IMU-131 will be evaluated by adverse events (AEs) and laboratory measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose of IMU-131 (Phase 1b)</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>The recommended phase 2 dose will be evaluated by safety/tolerability and immunogenicity data for IMU-131 (P467- specific antibodies (IgG) and Her-2- specific antibodies (IgG) titers).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical efficacy of IMU-131 (Phase 2)</measure>
    <time_frame>Day 0 to Death (Approximately 17.5 months)</time_frame>
    <description>To evaluate the clinical efficacy of IMU-131 based on overall survival (OS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To evaluate other efficacy measures of IMU-131: progression-free survival (PFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To evaluate other efficacy measures of IMU-131: time to progression (TTP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To evaluate other efficacy measures of IMU-131: disease control rate (DCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To evaluate other efficacy measures of IMU-131: objective response rate (ORR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To evaluate other efficacy measures of IMU-131: duration of objective response (DOR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Size (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To evaluate other efficacy measures of IMU-131: change in tumor size (CTS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellular immunogenicity of IMU-131(Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>Values and changes from randomization in humoral and cellular immunogenicity data including P467-specific antibodies (IgG), Her-2-specific antibodies (IgG), vaccine-specific cytokine levels and regulatory and effector T and B cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAE's (Phase 2)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>Safety will be assessed by comparing the incidence of TEAE's &amp; SAE's in each group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Outcome (Phase 1b): Humoral immunogenicity evaluated by P467-specific antibodies (IgG) and Her-2- specific antibodies (IgG)</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>Antibodies analysed in serum samples taken across study visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome (Phase 1b): Cellular immunogenicity evaluated by vaccine-specific cytokine levels as well as analysis of regulatory and effector T and B cells</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>Vaccine-specific cytokine levels and regulatory and effector T and B cells analysed in whole blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome (Phase 1b): Radiographic data measured by RECIST 1.1 criteria</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>Radiographic data will be analyzed descriptively to explore the Response Rate (RR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome (Phase 2): Measurement of Serum Prediction Marker of Tumor Progression</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To measure the changes from baseline of serum prediction marker of tumor progression in ng/ml.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome (Phase 2): Measurement of immunological and biochemical markers</measure>
    <time_frame>Day 0 to Progression (approx. 7.5 months)</time_frame>
    <description>To measure the changes from baseline of intra-tumor T cells and biochemical markers including CD4+, CD8+ T cells &amp; Treg cells in ng/ml.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - IMU 131 plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Chemotherapy only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMU-131</intervention_name>
    <description>IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2 - IMU 131 plus chemotherapy</arm_group_label>
    <other_name>HER-Vaxx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.</intervention_name>
    <description>Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2 - Chemotherapy only</arm_group_label>
    <arm_group_label>Phase 2 - IMU 131 plus chemotherapy</arm_group_label>
    <other_name>Standard of Care Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has been informed of the investigational nature of this study and has given&#xD;
             written informed consent in accordance with institutional, local, and national&#xD;
             guidelines;&#xD;
&#xD;
          2. Age ≥ 20 years old;&#xD;
&#xD;
          3. Life expectancy of at least 12 weeks;&#xD;
&#xD;
          4. Phase 1b: No prior chemotherapy or radiotherapy for advanced gastric or GEJ cancer&#xD;
             within 6 months prior to Day 0; Phase 2: No prior chemotherapy or radiotherapy for&#xD;
             advanced gastric or GEJ cancer within 3 months prior to Day 0;&#xD;
&#xD;
          5. Metastatic gastric or GEJ adenocarcinoma, or locally advanced disease not amenable to&#xD;
             surgical resection;&#xD;
&#xD;
          6. HER2/neu overexpression (3+ by immunohistochemistry (IHC) or if IHC 2+ confirmed by&#xD;
             fluorescent in situ hybridization [FISH] or chromogenic in situ hybridization [CISH]).&#xD;
             Patients with IHC 2+ expression without confirmation of overexpression by fluorescent&#xD;
             in situ hybridization [FISH] or chromogenic in situ hybridization [CISH]) may be&#xD;
             included in Phase 1b with agreement of Imugene Limited;&#xD;
&#xD;
          7. Phase 1b: ECOG performance status 0-1; Phase 2: ECOG performance status 0-2;&#xD;
&#xD;
          8. At least one measurable lesion as defined by RECIST 1.1 criteria. Patients with&#xD;
             non-measurable lesions may be included in Phase1b with agreement of Imugene Limited;&#xD;
&#xD;
          9. Adequate left ventricular ejection function at baseline, defined as LVEF &gt; 50% by&#xD;
             echocardiogram or MUGA scan (Multi Gated Acquisition Scan);&#xD;
&#xD;
         10. Adequate hematologic function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet&#xD;
             count ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL;&#xD;
&#xD;
         11. Adequate liver function evidenced by bilirubin ≤ 1.5 x laboratory upper limit of&#xD;
             normal [ULN], and ALT and AST ≤ 3 x laboratory ULN if no liver involvement or ALT and&#xD;
             AST ≤ 5 times laboratory ULN with liver involvement;&#xD;
&#xD;
         12. Adequate renal function (creatinine ≤ 1.5 x laboratory ULN);&#xD;
&#xD;
         13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
         14. Male and female patients of childbearing potential must agree to use a highly&#xD;
             effective method of contraception throughout the study and for at least 28 days after&#xD;
             the last dose of assigned treatment (see section 4.3 for details). A patient is of&#xD;
             childbearing potential if, in the opinion of the investigator, he/she is biologically&#xD;
             capable of having children and is sexually active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with trastuzumab or any other HER2/neu targeting antibody or agent;&#xD;
&#xD;
          2. Continuous systemic treatment with either corticosteroids (&gt;10 mg daily prednisone&#xD;
             equivalents) or other immunosuppressive medications within 4 weeks prior to first dose&#xD;
             of study treatment. Inhaled or topical steroids and physiological replacement doses of&#xD;
             up to 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             auto-immune disease;&#xD;
&#xD;
          3. Prior organ transplant;&#xD;
&#xD;
          4. Phase 1b: Patient not considered a candidate for 5-FU, capecitabine, or cisplatin&#xD;
             chemotherapy; Phase 2: Patient not considered a candidate for 5-FU, capecitabine,&#xD;
             cisplatin or oxaliplatin chemotherapy;&#xD;
&#xD;
          5. History of documented congestive heart failure; angina pectoris requiring antianginal&#xD;
             medication; evidence of transmural infarction on ECG; poorly controlled hypertension;&#xD;
             clinically significant valvular heart disease; high risk uncontrolled arrhythmias; or&#xD;
             New York Heart Association (NYHA) class II heart disease;&#xD;
&#xD;
          6. If on warfarin (Coumadin®) or other vitamin K antagonists;&#xD;
&#xD;
          7. Concurrent active malignancy except for adequately controlled limited basal cell&#xD;
             carcinoma of the skin;&#xD;
&#xD;
          8. Peripheral neuropathy or hearing loss of NCI CTCAE Grade &gt; 2;&#xD;
&#xD;
          9. History of uncontrolled seizures, central nervous disorders or psychiatric disability&#xD;
             judged by the investigator to be clinically significant and precluding informed&#xD;
             consent, participation in the study, or adversely affecting compliance to study drugs;&#xD;
&#xD;
         10. Active infection requiring IV antibiotics;&#xD;
&#xD;
         11. Positive for human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active&#xD;
             hepatitis B (HBsAg reactive) or active hepatitis C (HCV ribonucleic acid [RNA]&#xD;
             qualitative) infection;&#xD;
&#xD;
         12. Pregnant or lactating females;&#xD;
&#xD;
         13. Major surgery within 4 weeks prior to study entry. Minor surgery (excluding diagnostic&#xD;
             biopsy) within 1 week prior to study entry;&#xD;
&#xD;
         14. Has received a live-virus vaccination within 4 weeks of first study vaccination.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted;&#xD;
&#xD;
         15. Current or recent (within 4 weeks of first IMU-131 vaccination) treatment with another&#xD;
             investigational drug or participation in another investigational study.&#xD;
&#xD;
         16. Phase 2: Patients with a known diphtheria toxoid hypersensitivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Laeufle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imugene Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Cancer Center</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North East Cancer Hospital and Research Institute</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <zip>781023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shetty's Hospital</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Manavata Cancer Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNJ Institute of Oncology and Regional Cancer Centre</name>
      <address>
        <city>Hyderabad</city>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Medical Centre</name>
      <address>
        <city>Kolkata</city>
        <zip>700160</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCG NCHRI Cancer Centre</name>
      <address>
        <city>Nagpur</city>
        <zip>440026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre Indira Gandhi Institute of Medical Sciences</name>
      <address>
        <city>Patna</city>
        <zip>800014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine IMSP Institutul Oncologic</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <state>Južnobanatski Okrug</state>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology and Radiology of Serbia - PPDS</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Medical Oncology, Department of Medicine, Prince of Songkla University, Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla Province</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Thailand</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine LLC</name>
      <address>
        <city>Kapitanivka</city>
        <zip>8112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>India</country>
    <country>Moldova, Republic of</country>
    <country>Serbia</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <link>
    <url>http://www.imugene.com/</url>
    <description>Imugene (ASX: IMU) is a publicly-listed biotechnology company with operations in America and Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

